Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akagera liposomal long-acting injectable antibiotic
- Development stage
- Preclinical
- Lead developer
- Akagera Medicines
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injectable
01
Overview
Akagera liposomal long-acting injectable antibiotic is a preclinical therapeutic candidate being developed by Akagera Medicines for the treatment of tuberculosis (TB). The formulation utilizes a small molecule antibiotic encapsulated within liposomal nanoparticles, designed as a long-acting injectable (LAI) to provide sustained therapeutic levels over an extended period. Its primary mechanism of action involves phagocytosis-mediated uptake by macrophages, which are the primary cellular reservoir for *Mycobacterium tuberculosis*. By targeting these cells directly, the drug aims to enhance efficacy at the site of infection while potentially reducing systemic side effects and improving patient compliance through less frequent dosing compared to standard daily oral regimens.
- Other names
- Akagera TB LAIliposomal long-acting injectable antibiotic (tuberculosis)Akagera Medicines TB LAI
02
Targets
ATP Synthase70S ribosome (Bacterial protein synthesis ribosome complex)
Beyond the preview
Go deeper on Akagera liposomal long-acting injectable antibiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akagera liposomal long-acting injectable antibiotic.